GSK-J5 (hydrochloride)

07/19

ALTERNATE NAMES: N-[2-(3-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine, ethyl ester, monohydrochoride; ethyl 3-[[2-pyridin-3-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate hydrochloride

CATALOG #:
B2841-1 1 mg
B2841-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{24}H_{28}ClN_5O_2$

MOLECULAR WEIGHT: 454

CAS NUMBER: 1797983-32-4

APPEARANCE: A crystalline solid

PURITY: ≥95%

SOLUBILITY:
~20 mg/ml in Ethanol
~30 mg/ml in DMSO and DMF

DESCRIPTION: GSK-J5 is an isomer of GSK-J4 and a prodrug for negative control GSK-J2. GSK-J2 is a negative control for GSK-J1, which is an inhibitor of the H3K27 histone demethylases JMJD3 and UTX. GSK-J5 did not have any effect on TNF-α protein production that depends on both JMJD3 and UTX. GSK-J5 is a weak inhibitor of JMJD3.

STORAGE TEMPERATURE: -20ºC

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Kruidenier, L., Chung, C.W., Cheng, Z., et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response Nature 488, 404-408 (2012).

RELATED PRODUCTS:

GSK-J1 sodium salt (Cat. No. 2260)
GSK-J4 (Free base) (Cat. No. 2762)
GSK-J4 hydrochloride (Cat. No. 2259)
GSK-J2 (Sodium Salt) (Cat. No. B2813)
GSK-J1 (Free acid) (Cat. No. 2761)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***